ReviewNeuro-oncology2016
Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
Review in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- A Phase 2 Study of Dose-intensified Chemoradiation Using Biologically Based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma.International journal of radiation oncology, biology, physics · 2021Trial
- Combining quantitative susceptibility mapping, arterial spin labeling and diffusion weighted imaging for distinguishing true progression from pseudoprogression in high-grade gliomas.Neuroradiology · 2025Article
- Association Between the Volume Transfer Constant (KCancer reports (Hoboken, N.J.) · 2025Article
- An optimized tissue sampling scheme guided by MRI features reveals intratumoral heterogeneity in glioblastoma.Scientific reports · 2025Article
- Deep learning-based super-resolution and denoising algorithm improves reliability of dynamic contrast-enhanced MRI in diffuse glioma.Scientific reports · 2024Article
- Identification of a Single-Dose, Low-Flip-Angle-Based CBV Threshold for Fractional Tumor Burden Mapping in Recurrent Glioblastoma.AJNR. American journal of neuroradiology · 2024Article
- Glioblastomas with and without peritumoral fluid-attenuated inversion recovery (FLAIR) hyperintensity present morphological and microstructural differences on conventional MR images.European radiology · 2023Article
- Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors.NMR in biomedicine · 2023Article
- Assessment and prediction of glioblastoma therapy response: challenges and opportunities.Brain : a journal of neurology · 2023Article
- Identification of single-dose, dual-echo based CBV threshold for fractional tumor burden mapping in recurrent glioblastoma.Frontiers in oncology · 2023Article
- Sequential and Hybrid PET/MRI Acquisition in Follow-Up Examination of Glioblastoma Show Similar Diagnostic Performance.Cancers · 2022Article
- Feasibility of glioblastoma tissue response mapping with physiologic BOLD imaging using precise oxygen and carbon dioxide challenge.Magma (New York, N.Y.) · 2022Article
- High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques.Frontiers in oncology · 2022Review
- Multimodal assessment of disease activity in glioblastoma : A single center experience.Wiener klinische Wochenschrift · 2021Article
- Article
- Anti-angiogenesis in cancer therapeutics: the magic bullet.Journal of the Egyptian National Cancer Institute · 2021Review
- Theranostics in Boron Neutron Capture Therapy.Life (Basel, Switzerland) · 2021Review
- Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis.Journal of molecular neuroscience : MN · 2021Article
- Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors.Current oncology reports · 2021Review
- Imaging of intratumoral heterogeneity in high-grade glioma.Cancer letters · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Aside from bidimensional measurements from conventional contrast-enhanced MRI, there are no validated or FDA-qualified imaging biomarkers for high-grade gliomas. However, advanced functional MRI techniques, including perfusion- and diffusion-weighted MRI, have demonstrated much potential for determining prognosis, predicting therapeutic response, and assessing early treatment response. They may also prove useful for differentiating pseudoprogression from true progression after temozolomide chemoradiation and pseudoresponse from true response after anti-angiogenic therapy. This review will highlight recent developments using these techniques and emphasize the need for technical standardization and validation in prospective studies in order for these methods to become incorporated into standard-of-care imaging for brain tumor patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.